<DOC>
	<DOCNO>NCT00325403</DOCNO>
	<brief_summary>This study international , multicenter , randomize ( 2:1 active : placebo ) , double-blind , placebo-controlled study subject PAH NOT currently receive approve therapy PAH . Study visit occur 4 week interval 12 week ( additional visit Week 11 ) key measure efficacy 6-minute walk test . Study procedure include routine blood test , medical history , physical exam , disease evaluation , exercise test . Two optional substudies also part FREEDOM-M select center - hemodynamic substudy right heart catheterization Baseline Week 12 genetics biomarkers substudy blood sample collect Baseline Week 12 . Patients complete assessment 12 week also eligible enter open-label , extension phase study ( FREEDOM - EXT ) .</brief_summary>
	<brief_title>FREEDOM - M : Oral Treprostinil Monotherapy Treatment Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Between 12 75 year age , inclusive . Body weight least 40 kg Body Mass Index &lt; 45 PAH either idiopathic/heritable ; associate repair congenital systemictopulmonary shunt ( repair â‰¥ 5 year ) ; associate collagen vascular disease ; associate HIV . Previous test ( e.g. , right heart catheterization , echocardiography ) consistent diagnosis PAH . Baseline 6minute walk distance 200 425 meter , inclusive . Reliable cooperative protocol requirement . Nursing pregnant . Currently receive endothelin receptor antagonist , phosphodiesterase5 inhibitor , prostacyclin within 30 day Baseline . PAH due condition note inclusion criterion . History uncontrolled sleep apnea , renal insufficiency , anemia , leave sided heart disease , uncontrolled systemic hypertension , parenchymal lung disease . Use investigational drug within 30 day Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
</DOC>